Shares of PolyPid Ltd. (PYPD) are up 8% in pre-market, as the company makes progress with its lead program D-PLEX100.
D-PLEX100, PolyPid's lead product candidate, is designed to prevent surgical site infection (SSIs) using the company's PLEX local drug-delivery platform. The FDA has scheduled a face-to-face pre-NDA meeting, a key near-term catalyst for the program.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com